Bibliography
- Hazirolan D, Pleyer U. Think global–act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthal Res 2013;49(2):59-65
- Sen HN, Larson TA, Meleth AD, et al. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol 2012;153(6):1038-42
- Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 2011;118(1):184-90
- Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 2014;8:67-81
- Leung TG, Thorne JE. Emerging drugs for the treatment of uveitis. Expert Opin Emerg Drugs 2013;18(4):513-21
- Kruh J, Foster CS. The philosophy of treatment of uveitis: past, present and future. Dev Ophthalmol 2012;51:1-6
- Heo J, Sepah YJ, Yohannan J, et al. The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther 2012;12(8):995-1008
- Gomes Bittencourt M, Sepah YJ, Do DV, et al. New treatment options for noninfectious uveitis. Dev Ophthalmol 2012;51:134-61
- Agrawal R, Iyer J, Connolly J, et al. Cytokines and Biologics in non-infectious autoimmune uveitis: bench to bedside. Indian J Ophthalmol 2014;62(1):74-81
- Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past, present and future. BMC Ophthalmol 2013;13:18
- Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets 2013;12(1):38-45
- Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121(3):785-96. e3
- Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet’s uveitis: road to remission. Int Ophthalmol 2014;34(2):365-81
- Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11(1):35-9
- Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 2008;15(1):47-55
- Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18(6):481-6
- Chu DS, Johnson SJ, Mallya UG, et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthal inflamm Infect 2013;3(1):64
- Keane PA, Karampelas M, Sim DA, et al. Objective Measurement of Vitreous Inflammation Using Optical Coherence Tomography. Ophthalmology 2014;121(9):1706-14